查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2089702

長效注射藥物市場規模、佔有率和趨勢分析報告：按治療領域、分子類型、給藥途徑、分銷管道、地區和細分市場預測（2026-2033 年）

Long-acting Injectables Therapeutics Market Size, Share & Trends Analysis Report By Therapeutic Area, By Molecule Type, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

長效注射藥物市場概述

2025 年全球長效注射治療藥物市場價值為 183 億美元，預計從 2026 年到 2033 年將以 12.8% 的複合年成長率成長，到 2033 年達到 205 億美元至 477 億美元。

到2025年，北美將佔全球市場佔有率的41.8%，成為最大佔有率。受慢性病和複雜疾病緩釋療法需求不斷成長的推動，長效注射劑（LAI）市場正在發展成為先進藥物傳輸系統中的關鍵細分市場。

最初，長效注射劑主要用於治療精神疾病，特別是思覺失調症，但作為一種更廣泛的治療方法，它逐漸受到關注，因為它可以提高患者對藥物的依從性並減少給藥頻率。

這種轉變反映了整個行業向以患者為中心的護理模式轉變的趨勢，該模式優先考慮治療的便利性、長期疾病管理以及臨床療效。隨著醫療保健系統不斷強調以結果為導向的護理，長效注射劑（LAI）日益被認為是一種解決用藥依從性不足和提高整體治療連續性的策略解決方案。

長效注射劑（LAI）產業正經歷顯著的擴張，其應用範圍已超越傳統的精神科領域，在感染疾病、腫瘤輔助性治療治療和荷爾蒙療法等領域的應用日益廣泛。微球製劑、可生物分解的緩釋製劑和長效生物製藥等藥物傳遞技術的進步，使得給藥間隔從數週延長至數月。這些技術進步正在加速下一代療法的研發，從而改善藥物動力學特徵並減輕患者的負擔。製藥公司正積極投資拓展產品線並創新製劑，推動長效注射劑轉型為多用途治療平台，在全球醫療保健市場中發揮日益重要的臨床和商業性作用。

長效注射劑（LAI）產業的特點是研發投入增加、策略聯盟不斷加強，以及對注射藥物生命週期管理的日益重視。儘管由於這些療法成本高昂，定價和報銷問題仍然是重要的考量因素，但住院率的降低和患者療效的改善正在提升其價值提案。此外，長效製劑臨床證據的不斷累積和監管機構日益成長的關注正在推動市場發展，長效注射劑正逐漸成為未來藥物發行策略的關鍵組成部分。總而言之，在創新、療法多樣化以及全球對以提高用藥依從性為重點的治療方案日益成長的需求的推動下，該市場有望實現持續成長。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：長效注射劑市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章：長效注射劑市場：依治療領域分類的商業分析

  • 按治療區域分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：依治療領域分類，2021-2033年
  • 中樞神經系統疾病
  • 感染疾病
  • 代謝和內分泌疾病
  • 腫瘤學
  • 自體免疫/發炎性疾病
  • 其他治療領域

第5章：長效注射劑市場：按分子類型分類的業務分析

  • 按分子類型分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分子類型分類，2021-2033年
  • 小分子藥物
  • 生物製劑

第6章：長效注射劑市場：依給藥途徑進行業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 肌肉內注射（IM）
  • 皮下（SC）

第7章：長效注射劑市場：按通路分類的業務分析

  • 按分銷管道分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按分銷管道分類，2021-2033 年
  • 醫院藥房
  • 專科藥房
  • 零售藥房

第8章：長效注射劑市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第9章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Johnson & Johnson
    • Gilead Sciences
    • Eli Lilly and Company
    • AstraZeneca
    • Otsuka Pharmaceutical
    • Lundbeck
    • Pfizer
    • Takeda Pharmaceutical Company
    • Novartis AG
Product Code: GVR-4-68040-932-2

Long-acting Injectables Therapeutics Market Summary

The global long-acting injectables therapeutics market size was valued at USD 18.3 billion in 2025 and is projected to grow from USD 20.5 billion to USD 47.7 billion by 2033, at a CAGR of 12.8% from 2026 to 2033. North America held the largest share of 41.8% of the global market in 2025. The LAI therapeutics market is evolving into a prominent segment within advanced drug delivery systems, driven by the growing need for sustained-release treatment options across chronic and complex diseases.

Initially concentrated in the management of psychiatric disorders, particularly schizophrenia, LAIs have progressively gained traction as a broader therapeutic approach that enhances patient adherence and reduces the frequency of dosing.

This shift reflects a wider industry movement toward patient-centric care models, where treatment convenience and long-term disease control are prioritized alongside clinical efficacy. As healthcare systems continue to emphasize outcomes-based care, LAIs are increasingly being recognized as a strategic solution to address medication non-compliance and improve overall treatment continuity.

The industry is experiencing significant expansion beyond its traditional psychiatric applications, with growing adoption in infectious diseases, oncology support therapies, and hormonal treatments. Advancements in drug delivery technologies, including microsphere-based formulations, biodegradable depots, and long-acting biologics, are enabling extended dosing intervals ranging from weeks to several months. This technological progress is facilitating the development of next-generation therapies that offer improved pharmacokinetic profiles and reduced treatment burden. Pharmaceutical companies are actively investing in pipeline expansion and formulation innovation, supporting the transition of LAIs into a multi-therapeutic platform with increasing clinical and commercial relevance across global healthcare markets.

The LAI therapeutics industry is characterized by rising investments in research and development, strategic collaborations, and growing emphasis on lifecycle management of injectable products. While pricing and reimbursement challenges remain key considerations due to the premium nature of these therapies, their value proposition is strengthened by reduced hospitalization rates and improved patient outcomes. The market is further supported by expanding clinical evidence and regulatory interest in long-acting formulations, positioning LAIs as a critical component of future drug delivery strategies. Overall, the market is moving toward sustained growth, underpinned by innovation, therapeutic diversification, and increasing global demand for adherence-focused treatment solutions.

Global Long-acting Injectables Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global long-acting injectables therapeutics market report based on therapeutic area, molecule type, route of administration, distribution channel, and region:

  • Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
  • Central Nervous System (CNS) Disorders
  • Infectious Diseases
  • Metabolic & Endocrine Disorders
  • Oncology
  • Autoimmune & Inflammatory Diseases
  • Other Therapeutic Areas
  • Molecule Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Small Molecules
  • Biologics
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Intramuscular (IM)
  • Subcutaneous (SC)
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Specialty Pharmacies
  • Retail Pharmacies
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapeutic Area
    • 1.2.2. Molecule Type
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Long-acting Injectables Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Long-acting Injectables Therapeutics Market: Therapeutic Area Business Analysis

  • 4.1. Therapeutic Area Market Share, 2025 & 2033
  • 4.2. Therapeutic Area Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Billion)
  • 4.4. Central Nervous System (CNS) Disorders
    • 4.4.1. Central Nervous System (CNS) Disorders Market, 2021 - 2033 (USD Billion)
  • 4.5. Infectious Diseases
    • 4.5.1. Infectious Diseases Market, 2021 - 2033 (USD Billion)
  • 4.6. Metabolic & Endocrine Disorders
    • 4.6.1. Metabolic & Endocrine Disorders Market, 2021 - 2033 (USD Billion)
  • 4.7. Oncology
    • 4.7.1. Oncology Market, 2021 - 2033 (USD Billion)
  • 4.8. Autoimmune & Inflammatory Diseases
    • 4.8.1. Autoimmune & Inflammatory Diseases Market, 2021 - 2033 (USD Billion)
  • 4.9. Other Therapeutic Areas
    • 4.9.1. Other Therapeutic Areas Market, 2021 - 2033 (USD Billion)

Chapter 5. Long-acting Injectables Therapeutics Market: Molecule Type Business Analysis

  • 5.1. Molecule Type Market Share, 2025 & 2033
  • 5.2. Molecule Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Billion)
  • 5.4. Small Molecules
    • 5.4.1. Small Molecules Market, 2021 - 2033 (USD Billion)
  • 5.5. Biologics
    • 5.5.1. Biologics Market, 2021 - 2033 (USD Billion)

Chapter 6. Long-acting Injectables Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
  • 6.4. Intramuscular (IM)
    • 6.4.1. Intramuscular (IM) Market, 2021 - 2033 (USD Billion)
  • 6.5. Subcutaneous (SC)
    • 6.5.1. Subcutaneous (SC) Market, 2021 - 2033 (USD Billion)

Chapter 7. Long-acting Injectables Therapeutics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2025 & 2033
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.5. Specialty Pharmacies
    • 7.5.1. Specialty Pharmacies Market, 2021 - 2033 (USD Billion)
  • 7.6. Retail Pharmacies
    • 7.6.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 8. Long-acting Injectables Therapeutics Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2025 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. North America Long-acting Injectables Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Target Disease Prevalence
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. Reimbursement Framework
      • 8.4.2.5. U.S. Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Target Disease Prevalence
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Reimbursement Framework
      • 8.4.3.5. Canada Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Target Disease Prevalence
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Reimbursement Framework
      • 8.4.4.5. Mexico Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.5. Europe
    • 8.5.1. Europe Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Target Disease Prevalence
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. Reimbursement Framework
      • 8.5.2.5. UK Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Target Disease Prevalence
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Reimbursement Framework
      • 8.5.3.5. Germany Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Target Disease Prevalence
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. Reimbursement Framework
      • 8.5.4.5. France Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Target Disease Prevalence
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Reimbursement Framework
      • 8.5.5.5. Italy Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Target Disease Prevalence
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Reimbursement Framework
      • 8.5.6.5. Spain Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Target Disease Prevalence
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Reimbursement Framework
      • 8.5.7.5. Denmark Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Target Disease Prevalence
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Reimbursement Framework
      • 8.5.8.5. Sweden Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Target Disease Prevalence
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Reimbursement Framework
      • 8.5.9.5. Norway Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Target Disease Prevalence
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Reimbursement Framework
      • 8.6.2.5. Japan Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Target Disease Prevalence
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. Reimbursement Framework
      • 8.6.3.5. China Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Target Disease Prevalence
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. Reimbursement Framework
      • 8.6.4.5. India Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Target Disease Prevalence
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Reimbursement Framework
      • 8.6.5.5. Australia Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Target Disease Prevalence
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. Reimbursement Framework
      • 8.6.6.5. South Korea Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Target Disease Prevalence
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Reimbursement Framework
      • 8.6.7.5. Thailand Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.7. Latin America
    • 8.7.1. Latin America Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Target Disease Prevalence
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Reimbursement Framework
      • 8.7.2.5. Brazil Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Target Disease Prevalence
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Reimbursement Framework
      • 8.7.3.5. Argentina Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 8.8. Middle East and Africa
    • 8.8.1. Middle East and Africa Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Target Disease Prevalence
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. Reimbursement Framework
      • 8.8.2.5. South Africa Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Target Disease Prevalence
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Reimbursement Framework
      • 8.8.3.5. Saudi Arabia Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Target Disease Prevalence
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. Reimbursement Framework
      • 8.8.4.5. UAE Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Target Disease Prevalence
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Reimbursement Framework
      • 8.8.5.5. Kuwait Long-acting Injectables Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Johnson & Johnson
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Gilead Sciences
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Eli Lilly and Company
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. AstraZeneca
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Otsuka Pharmaceutical
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. Lundbeck
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. Pfizer
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Takeda Pharmaceutical Company
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Novartis AG
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global long-acting injectables therapeutics market, by region, 2021 - 2033 (USD Billion)
  • Table 4 Global long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 5 Global long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 6 Global long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 7 Global long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 8 North America long-acting injectables therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 9 North America long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 10 North America long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 11 North America long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 12 North America long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 13 U.S. long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 14 U.S. long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 15 U.S. long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 16 U.S. long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 17 Canada long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 18 Canada long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 19 Canada long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 20 Canada long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 21 Mexico long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 22 Mexico long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 23 Mexico long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 24 Mexico long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 25 Europe long-acting injectables therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 26 Europe long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 27 Europe long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 28 Europe long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 29 Europe long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 30 UK long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 31 UK long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 32 UK long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 33 UK long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 34 Germany long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 35 Germany long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 36 Germany long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 37 Germany long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 38 France long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 39 France long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 40 France long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 41 France long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 42 Italy long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 43 Italy long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 44 Italy long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 45 Italy long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 46 Spain long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 47 Spain long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 48 Spain long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 49 Spain long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 50 Norway long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 51 Norway long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 52 Norway long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 53 Norway long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 54 Denmark long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 55 Denmark long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 56 Denmark long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 57 Denmark long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 58 Sweden long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 59 Sweden long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 60 Sweden long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 61 Sweden long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 62 Asia Pacific long-acting injectables therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 63 Asia Pacific long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 64 Asia Pacific long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 65 Asia Pacific long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 66 Asia Pacific long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 67 Japan long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 68 Japan long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 69 Japan long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 70 Japan long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 71 China long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 72 China long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 73 China long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 74 China long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 75 India long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 76 India long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 77 India long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 78 India long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 79 Australia long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 80 Australia long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 81 Australia long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 82 Australia long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 83 South Korea long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 84 South Korea long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 85 South Korea long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 86 South Korea long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 87 Thailand long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 88 Thailand long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 89 Thailand long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 90 Thailand long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 91 Latin America long-acting injectables therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 92 Latin America long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 93 Latin America long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 94 Latin America long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 95 Latin America long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 96 Brazil long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 97 Brazil long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 98 Brazil long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 99 Brazil long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 100 Argentina long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 101 Argentina long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 102 Argentina long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 103 Argentina long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 104 Middle East & Africa long-acting injectables therapeutics market, by country, 2021 - 2033 (USD Billion)
  • Table 105 Middle East & Africa long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 106 Middle East & Africa long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 107 Middle East & Africa long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 108 Middle East & Africa long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 109 South Africa long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 110 South Africa long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 111 South Africa long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 112 South Africa long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 113 Saudi Arabia long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 114 Saudi Arabia long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 115 Saudi Arabia long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 116 Saudi Arabia long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 117 UAE long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 118 UAE long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 119 UAE long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 120 UAE long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)
  • Table 121 Kuwait long-acting injectables therapeutics market, by therapeutic area, 2021 - 2033 (USD Billion)
  • Table 122 Kuwait long-acting injectables therapeutics market, by molecule type, 2021 - 2033 (USD Billion)
  • Table 123 Kuwait long-acting injectables therapeutics market, by route of administration, 2021 - 2033 (USD Billion)
  • Table 124 Kuwait long-acting injectables therapeutics market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Long-acting injectables therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Long-acting injectables therapeutics market dynamics
  • Fig. 11 Long-acting injectables therapeutics market: Porter's five forces analysis
  • Fig. 12 Long-acting injectables therapeutics market: PESTLE analysis
  • Fig. 13 Therapeutic area market, 2021 - 2033 (USD Billion)
  • Fig. 14 Central nervous system (CNS) disorders market, 2021 - 2033 (USD Billion)
  • Fig. 15 Infectious diseases market, 2021 - 2033 (USD Billion)
  • Fig. 16 Metabolic & endocrine disorders market, 2021 - 2033 (USD Billion)
  • Fig. 17 Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 18 Autoimmune & inflammatory diseases market, 2021 - 2033 (USD Billion)
  • Fig. 19 Other therapeutic areas market, 2021 - 2033 (USD Billion)
  • Fig. 20 Molecule type market, 2021 - 2033 (USD Billion)
  • Fig. 21 Small molecules market, 2021 - 2033 (USD Billion)
  • Fig. 22 Biologics market, 2021 - 2033 (USD Billion)
  • Fig. 23 Route of administration market, 2021 - 2033 (USD Billion)
  • Fig. 24 Intramuscular (IM) market, 2021 - 2033 (USD Billion)
  • Fig. 25 Subcutaneous (SC) market, 2021 - 2033 (USD Billion)
  • Fig. 26 Distribution channel market, 2021 - 2033 (USD Billion)
  • Fig. 27 Hospital pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 28 Specialty pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 29 Retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 30 Long-acting injectables therapeutics market revenue, by region
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 North America Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 33 U.S. country dynamics
  • Fig. 34 U.S. Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 35 Canada country dynamics
  • Fig. 36 Canada Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 37 Mexico country dynamics
  • Fig. 38 Mexico Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 39 Europe Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 44 France country dynamics
  • Fig. 45 France Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 52 Sweden country dynamics
  • Fig. 53 Sweden Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 54 Denmark country dynamics
  • Fig. 55 Denmark Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 56 Asia Pacific Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 59 China country dynamics
  • Fig. 60 China Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 61 India country dynamics
  • Fig. 62 India Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 63 Australia country dynamics
  • Fig. 64 Australia Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 65 South Korea country dynamics
  • Fig. 66 South Korea Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 69 Latin America Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 72 Argentina country dynamics
  • Fig. 73 Argentina Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 74 MEA Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 75 South Africa country dynamics
  • Fig. 76 South Africa Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 77 Saudi Arabia country dynamics
  • Fig. 78 Saudi Arabia Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 79 UAE country dynamics
  • Fig. 80 UAE Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 81 Kuwait country dynamics
  • Fig. 82 Kuwait Long-acting injectables therapeutics market, 2021 - 2033 (USD Billion)
  • Fig. 83 Company categorization
  • Fig. 84 Company market position analysis
  • Fig. 85 Strategic framework